Zydus Lifesciences
ZYDUSLIFE
Zydus Lifesciences Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 3,72,928 |
| Weekly | 5.99% | 41,57,710 |
| Monthly | 14.05% | 1,62,06,071 |
Zydus Lifesciences Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| ZYDUSLIFE | - | 5.99% | 14.05% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Zydus Lifesciences Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| ZYDUSLIFE | 24.79 | 2.40 | 13.74 | 11.06 | 11.64 | 0.57 |
| Index | 36.20 | 6.77 | 17.25 | 17.89 | 19.69 | 1.20 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Zydus Lifesciences Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | 4.29% | -18.20% | 11.06% | 11.64% |
| FY '20-21 | 7.32% | 46.05% | 15.59% | 12.68% |
| FY '19-20 | 6.44% | -20.71% | 12.79% | 11.87% |
Zydus Lifesciences Shareholding Pattern
Zydus Lifesciences Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 11,623.55 | 9,000.35 | 2,831.10 | 1,592.15 |
| FY '20-21 | 11,091.75 | 8,245.40 | 2,915.35 | 1,840.90 |
| FY '19-20 | 10,551.40 | 8,417.25 | 2,619 | 1,294.25 |
Zydus Lifesciences Share Price
Zydus Lifesciences Ltd. is an Indian life sciences company. The Company is engaged in the research and development, manufacturing, marketing and sale of human medicines, such as generic medicines and specialty products, including biosimilars and vaccines; active pharmaceutical ingredients (API); animal health products and consumer protection products. Its products include Bilypsa (saroglitisar), Oxemia (desidustat), Ujvira (biologically similar to Kadcyla), and Exemptia. It offers Bilypsa for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Desidustat is an oral, small molecule, hypoxia-inducible factor-prolyl-hydroxylase (HIF-PH) inhibitor used to treat anemia in patients with chronic kidney disease (CKD). He is also developing an oral ZYIL1 small molecule to selectively suppress inflammation caused by the NLRP3 inflammasome. Its ZyCoV-D is a plasmid deoxyribonucleic acid (DNA) vaccine against COVID-19.